1887

Abstract

Purpose. In this study, we prepared GapC1-150-IsdB126-361-TRAP (GIT) proteins plus heat-labile enterotoxin B (LTB) as an intra-molecular adjuvant, together with CpG to further enhance its immunogenicity.

Methodology. Initially, the target genes were acquired and inserted into pET-32a (+) vectors to express LTB–GIT protein. LTB–GIT expression was confirmed by Western blotting and its immunocompetence was estimated through ELISA. Further, we immunized BALB/c mice with the LTB–GIT plus CpG adjuvant. After the second immunization, the antigen-specific CD4 cell responses for IFN-γ, IL-2, IL-4 and IL-10 were monitored by intracellular cytokine staining (ICS) assay. After the third immunization, the level of IgG antibodies in the serum from immunized groups was assessed by ELISA, and the protective immune response was appraised by Staphylococcus aureus and Streptococcus dysgalactiae challenge.

Results. The ELISA results showed that the OD450nm value of the LTB–GIT group was significantly higher than that of the BSA group. The group immunized with LTB–GIT plus CpG exhibited significantly stronger CD4 T cell responses for IFN-γ, IL-2, IL-4 and IL-10 compared to the group immunized with LTB–GIT, GIT alone orLTB–GIT plus CpG. In addition, the group immunized with LTB–GIT plus CpG generated the highest level of IgG antibodies against GIT among all of the groups, and our results also showed that LTB–GIT plus CpG markedly improved the survival percentage of mice compared to other groups.

Conclusion. We confirmed that the novel double adjuvants, LTB and CpG, are able to significantly improve GIT-induced immune responses. This formula could be a promising strategy for enhancing the immune efficacy of multi-subunit vaccines against Staphylococcus aureus and streptococcal infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000666
2018-01-17
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/3/432.html?itemId=/content/journal/jmm/10.1099/jmm.0.000666&mimeType=html&fmt=ahah

References

  1. Abid L, Charfeddine S, Kammoun S. Isolated Streptococcus agalactiae tricuspid endocarditis in elderly patient without known predisposing factors: case report and review of the literature. J Saudi Heart Assoc 2016; 28: 119– 123 [CrossRef] [PubMed]
    [Google Scholar]
  2. França SA, Braga JF, Moreira MV, Silva VC, Souza EF et al. Splendore-Hoeppli phenomenon in a cat with osteomyelitis caused by Streptococcus species. J Feline Med Surg 2014; 16: 189– 193 [CrossRef] [PubMed]
    [Google Scholar]
  3. Althaqafi AO, Matar MJ, Moghnieh R, Alothman AF, Alenazi TH et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia. Infect Drug Resist 2017; 10: 49– 55 [CrossRef] [PubMed]
    [Google Scholar]
  4. Deb R, Kumar A, Chakraborty S, Verma AK, Tiwari R et al. Trends in diagnosis and control of bovine mastitis: a review. Pak J Biol Sci 2013; 16: 1653– 1661 [CrossRef] [PubMed]
    [Google Scholar]
  5. Mehraj J, Akmatov MK, Strömpl J, Gatzemeier A, Layer F et al. Methicillin-sensitive and methicillin-resistant Staphylococcus aureus nasal carriage in a random sample of non-hospitalized adult population in northern Germany. PLoS One 2014; 9: e107937 [CrossRef] [PubMed]
    [Google Scholar]
  6. Kim L, Mcgee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev 2016; 29: 525– 552 [CrossRef] [PubMed]
    [Google Scholar]
  7. Ray D, Saha S, Sinha S, Pal NK, Bhattacharya B. Molecular characterization and evaluation of the emerging antibiotic-resistant Streptococcus pyogenes from eastern India. BMC Infect Dis 2016; 16: 753 [CrossRef] [PubMed]
    [Google Scholar]
  8. Yu L, Fan Z, Ma J, Tong C, Song B et al. Cross-protective effect of a novel multi-antigen-chimeric vaccine against Streptococcus and Staphylococcus aureus infection in mice. J Med Microbiol 2014; 63: 1732– 1740 [CrossRef] [PubMed]
    [Google Scholar]
  9. Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccines 2011; 10: 695– 708 [CrossRef] [PubMed]
    [Google Scholar]
  10. Moschioni M, Pansegrau W, Barocchi MA. Adhesion determinants of the Streptococcus species. Microb Biotechnol 2010; 3: 370– 388 [CrossRef] [PubMed]
    [Google Scholar]
  11. Rajagopal L. Understanding the regulation of Group B Streptococcal virulence factors. Future Microbiol 2009; 4: 201– 221 [CrossRef] [PubMed]
    [Google Scholar]
  12. Dedent A, Kim HK, Missiakas D, Schneewind O. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin Immunopathol 2012; 34: 317– 333 [CrossRef] [PubMed]
    [Google Scholar]
  13. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012; 2: 16 [CrossRef] [PubMed]
    [Google Scholar]
  14. Ebner P, Rinker J, Nguyen MT, Popella P, Nega M et al. Excreted cytoplasmic proteins contribute to pathogenicity in Staphylococcus aureus. Infect Immun 2016; 84: 1672– 1681 [CrossRef] [PubMed]
    [Google Scholar]
  15. Wang K, Lu C. Adhesion activity of glyceraldehyde-3-phosphate dehydrogenase in a Chinese Streptococcus suis type 2 strain. Berl Munch Tierarztl Wochenschr 2007; 120: 207– 209 [PubMed]
    [Google Scholar]
  16. Fu Q, Wei Z, Liu X, Xiao P, Lu Z et al. Glyceraldehyde-3-phosphate dehydrogenase, an immunogenic Streptococcus equi ssp. zooepidemicus adhesion protein and protective antigen. J Microbiol Biotechnol 2013; 23: 579– 585 [CrossRef] [PubMed]
    [Google Scholar]
  17. Goji N, Potter AA, Perez-Casal J. Characterization of two proteins of Staphylococcus aureus isolated from bovine clinical mastitis with homology to glyceraldehyde-3-phosphate dehydrogenase. Vet Microbiol 2004; 99: 269– 279 [CrossRef] [PubMed]
    [Google Scholar]
  18. Zhu H, Zhu Z, Cui Y, Zhang J, Liu L et al. GAPDH activity and immunogenicity of Staphylococcus aureus recombinant GapC protein. Sheng Wu Gong Cheng Xue Bao 2008; 24: 754– 759 [CrossRef] [PubMed]
    [Google Scholar]
  19. Yu L, Wang N, Ma J, Tong C, Song B et al. Improved protective efficacy of a chimeric Staphylococcus aureus vaccine candidate iron-regulated surface determinant B (N 126- P 361) -target of RNAIII activating protein in mice. Microbiol Immunol 2013; 57: 857– 864 [CrossRef] [PubMed]
    [Google Scholar]
  20. Nashar TO, Hirst TR, Williams NA. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology 1997; 91: 572– 578 [CrossRef] [PubMed]
    [Google Scholar]
  21. Ma Y. Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants. Expert Rev Vaccines 2016; 15: 1361– 1371 [CrossRef] [PubMed]
    [Google Scholar]
  22. Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004; 4: 937– 946 [CrossRef] [PubMed]
    [Google Scholar]
  23. Kulis M, Gorentla B, Burks AW, Zhong XP. Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. Mol Nutr Food Res 2013; 57: 906– 915 [CrossRef] [PubMed]
    [Google Scholar]
  24. Miernikiewicz P, Owczarek B, Piotrowicz A, Boczkowska B, Rzewucka K et al. Recombinant expression and purification of T4 phage Hoc, Soc, gp23, gp24 proteins in native conformations with stability studies. PLoS One 2012; 7: e38902 [CrossRef] [PubMed]
    [Google Scholar]
  25. Tayebi H, Lienard A, Billot M, Tiberghien P, Hervé P et al. Detection of intracellular cytokines in citrated whole blood or marrow samples by flow cytometry. J Immunol Methods 1999; 229: 121– 130 [CrossRef] [PubMed]
    [Google Scholar]
  26. Ma J, Wang H, Zheng X, Xue X, Wang B et al. CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int Immunopharmacol 2014; 19: 74– 80 [CrossRef] [PubMed]
    [Google Scholar]
  27. Ma Y, Luo Y, Huang X, Song F, Liu G. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology 2012; 158: 498– 504 [CrossRef] [PubMed]
    [Google Scholar]
  28. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247– 258 [CrossRef] [PubMed]
    [Google Scholar]
  29. Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011; 86: 1230– 1243 [CrossRef] [PubMed]
    [Google Scholar]
  30. Randerath O, König D, Saalmann M, Jansen B, Pulverer G. Prevention of infection with Streptococcus pneumoniae. Med Klin 2000; 95: 678– 682 [Crossref]
    [Google Scholar]
  31. Lalonde M, Segura M, Lacouture S, Gottschalk M. Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiology 2000; 146: 1913– 1921 [CrossRef] [PubMed]
    [Google Scholar]
  32. Ramírez NF, Keefe G, Dohoo I, Sánchez J, Arroyave O et al. Herd- and cow-level risk factors associated with subclinical mastitis in dairy farms from the high plains of the northern Antioquia, Colombia. J Dairy Sci 2014; 97: 4141– 4150 [CrossRef] [PubMed]
    [Google Scholar]
  33. Zadoks RN, Middleton JR, McDougall S, Katholm J, Schukken YH. Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans. J Mammary Gland Biol Neoplasia 2011; 16: 357– 372 [CrossRef] [PubMed]
    [Google Scholar]
  34. Stewart-Tull DE. The use of adjuvants in experimental vaccines : II. water-in-oil emulsions: Freund's complete and lncomplete adjuvants. Methods Mol Med 1996; 4: 141– 145 [CrossRef] [PubMed]
    [Google Scholar]
  35. de Haan L, Verweij WR, Feil IK, Holtrop M, Hol WG et al. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology 1998; 94: 424– 430 [CrossRef] [PubMed]
    [Google Scholar]
  36. Nakagawa I, Takahashi I, Kiyono H, McGhee JR, Hamada S. Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches. J Infect Dis 1996; 173: 1428– 1436 [CrossRef] [PubMed]
    [Google Scholar]
  37. Ola TO, Williams NA. Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit. Immunology 2006; 117: 262– 270 [CrossRef] [PubMed]
    [Google Scholar]
  38. Negri DR, Pinto D, Vendetti S, Patrizio M, Sanchez M et al. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect Immun 2009; 77: 1924– 1935 [CrossRef] [PubMed]
    [Google Scholar]
  39. Ji J, Griffiths KL, Milburn PJ, Hirst TR, O'Neill HC. The B subunit of Escherichia coli heat-labile toxin alters the development and antigen-presenting capacity of dendritic cells. J Cell Mol Med 2015; 19: 2019– 2031 [CrossRef] [PubMed]
    [Google Scholar]
  40. Matousek MP, Nedrud JG, Harding CV. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J Immunol 1996; 156: 4137– 4145 [PubMed]
    [Google Scholar]
  41. Qiao X, Li G, Wang X, Li X, Liu M et al. Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice. BMC Microbiol 2009; 9: 249 [CrossRef] [PubMed]
    [Google Scholar]
  42. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709– 760 [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000666
Loading
/content/journal/jmm/10.1099/jmm.0.000666
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error